Perampanel tolerability in children and adolescents with focal epilepsy: Effects on behavior and executive functions

Francesca Felicia Operto, Grazia Maria Giovanna Pastorino, Roberta Mazza, Carlo Di Bonaventura, Sara Matricardi, Alberto Verrotti, Marco Carotenuto, Andrea Viggiano, Giangennaro Coppola, Maurizio Elia

Research output: Contribution to journalArticle

Abstract

Objectives: Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist recently approved for focal and generalized epilepsies as an add-on therapy. It is well tolerated and effective as treatment of various pediatric epilepsy syndromes; PER does not seem to negatively affect the cognitive profile of children and adolescents, but its influence on executive functions is still to be assessed. Methods: Our sample included 37 children aged 12–18 years, with focal pharmacoresistant epilepsy already in therapy with 2 or 3 antiepileptic drug (AED); PER was added with 1 mg/week increments up to a dose of 2–4 mg/day. Changes in executive functions were assessed by the EpiTrack Junior test. Emotional and behavioral aspects were evaluated through the interview for parents Child Behavior Checklist (CBCL). Both tests were performed before taking PER and after 6 and 12 months of treatment. Results: After 12 months of PER in 22/30 patients, global score of the EpiTrack Junior test remained almost unchanged; in 7/30 patients, this score improved. The CBCL did not show significant changes in emotional or behavioral problems. Conclusions: Adjunctive treatment with PER did not negatively affect executive functions that could also be improved. No emotional/behavioral negative effects have been reported, and this suggests a good tolerability in the middle/long term.

Original languageEnglish
Article number106879
JournalEpilepsy and Behavior
DOIs
Publication statusAccepted/In press - Jan 1 2020

Fingerprint

Partial Epilepsy
Executive Function
Child Behavior
Checklist
Therapeutics
Generalized Epilepsy
Excitatory Amino Acid Antagonists
AMPA Receptors
Anticonvulsants
perampanel
Epilepsy
Parents
Interviews
Pediatrics
Acids

Keywords

  • Adverse effects
  • Behavior
  • Children
  • Executive functions
  • Perampanel

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Behavioral Neuroscience

Cite this

Operto, F. F., Pastorino, G. M. G., Mazza, R., Di Bonaventura, C., Matricardi, S., Verrotti, A., ... Elia, M. (Accepted/In press). Perampanel tolerability in children and adolescents with focal epilepsy: Effects on behavior and executive functions. Epilepsy and Behavior, [106879]. https://doi.org/10.1016/j.yebeh.2019.106879

Perampanel tolerability in children and adolescents with focal epilepsy : Effects on behavior and executive functions. / Operto, Francesca Felicia; Pastorino, Grazia Maria Giovanna; Mazza, Roberta; Di Bonaventura, Carlo; Matricardi, Sara; Verrotti, Alberto; Carotenuto, Marco; Viggiano, Andrea; Coppola, Giangennaro; Elia, Maurizio.

In: Epilepsy and Behavior, 01.01.2020.

Research output: Contribution to journalArticle

Operto, FF, Pastorino, GMG, Mazza, R, Di Bonaventura, C, Matricardi, S, Verrotti, A, Carotenuto, M, Viggiano, A, Coppola, G & Elia, M 2020, 'Perampanel tolerability in children and adolescents with focal epilepsy: Effects on behavior and executive functions', Epilepsy and Behavior. https://doi.org/10.1016/j.yebeh.2019.106879
Operto, Francesca Felicia ; Pastorino, Grazia Maria Giovanna ; Mazza, Roberta ; Di Bonaventura, Carlo ; Matricardi, Sara ; Verrotti, Alberto ; Carotenuto, Marco ; Viggiano, Andrea ; Coppola, Giangennaro ; Elia, Maurizio. / Perampanel tolerability in children and adolescents with focal epilepsy : Effects on behavior and executive functions. In: Epilepsy and Behavior. 2020.
@article{b0e2d9e3f1784ff4a7532aca8a2700d8,
title = "Perampanel tolerability in children and adolescents with focal epilepsy: Effects on behavior and executive functions",
abstract = "Objectives: Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist recently approved for focal and generalized epilepsies as an add-on therapy. It is well tolerated and effective as treatment of various pediatric epilepsy syndromes; PER does not seem to negatively affect the cognitive profile of children and adolescents, but its influence on executive functions is still to be assessed. Methods: Our sample included 37 children aged 12–18 years, with focal pharmacoresistant epilepsy already in therapy with 2 or 3 antiepileptic drug (AED); PER was added with 1 mg/week increments up to a dose of 2–4 mg/day. Changes in executive functions were assessed by the EpiTrack Junior test. Emotional and behavioral aspects were evaluated through the interview for parents Child Behavior Checklist (CBCL). Both tests were performed before taking PER and after 6 and 12 months of treatment. Results: After 12 months of PER in 22/30 patients, global score of the EpiTrack Junior test remained almost unchanged; in 7/30 patients, this score improved. The CBCL did not show significant changes in emotional or behavioral problems. Conclusions: Adjunctive treatment with PER did not negatively affect executive functions that could also be improved. No emotional/behavioral negative effects have been reported, and this suggests a good tolerability in the middle/long term.",
keywords = "Adverse effects, Behavior, Children, Executive functions, Perampanel",
author = "Operto, {Francesca Felicia} and Pastorino, {Grazia Maria Giovanna} and Roberta Mazza and {Di Bonaventura}, Carlo and Sara Matricardi and Alberto Verrotti and Marco Carotenuto and Andrea Viggiano and Giangennaro Coppola and Maurizio Elia",
year = "2020",
month = "1",
day = "1",
doi = "10.1016/j.yebeh.2019.106879",
language = "English",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Perampanel tolerability in children and adolescents with focal epilepsy

T2 - Effects on behavior and executive functions

AU - Operto, Francesca Felicia

AU - Pastorino, Grazia Maria Giovanna

AU - Mazza, Roberta

AU - Di Bonaventura, Carlo

AU - Matricardi, Sara

AU - Verrotti, Alberto

AU - Carotenuto, Marco

AU - Viggiano, Andrea

AU - Coppola, Giangennaro

AU - Elia, Maurizio

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Objectives: Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist recently approved for focal and generalized epilepsies as an add-on therapy. It is well tolerated and effective as treatment of various pediatric epilepsy syndromes; PER does not seem to negatively affect the cognitive profile of children and adolescents, but its influence on executive functions is still to be assessed. Methods: Our sample included 37 children aged 12–18 years, with focal pharmacoresistant epilepsy already in therapy with 2 or 3 antiepileptic drug (AED); PER was added with 1 mg/week increments up to a dose of 2–4 mg/day. Changes in executive functions were assessed by the EpiTrack Junior test. Emotional and behavioral aspects were evaluated through the interview for parents Child Behavior Checklist (CBCL). Both tests were performed before taking PER and after 6 and 12 months of treatment. Results: After 12 months of PER in 22/30 patients, global score of the EpiTrack Junior test remained almost unchanged; in 7/30 patients, this score improved. The CBCL did not show significant changes in emotional or behavioral problems. Conclusions: Adjunctive treatment with PER did not negatively affect executive functions that could also be improved. No emotional/behavioral negative effects have been reported, and this suggests a good tolerability in the middle/long term.

AB - Objectives: Perampanel (PER) is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist recently approved for focal and generalized epilepsies as an add-on therapy. It is well tolerated and effective as treatment of various pediatric epilepsy syndromes; PER does not seem to negatively affect the cognitive profile of children and adolescents, but its influence on executive functions is still to be assessed. Methods: Our sample included 37 children aged 12–18 years, with focal pharmacoresistant epilepsy already in therapy with 2 or 3 antiepileptic drug (AED); PER was added with 1 mg/week increments up to a dose of 2–4 mg/day. Changes in executive functions were assessed by the EpiTrack Junior test. Emotional and behavioral aspects were evaluated through the interview for parents Child Behavior Checklist (CBCL). Both tests were performed before taking PER and after 6 and 12 months of treatment. Results: After 12 months of PER in 22/30 patients, global score of the EpiTrack Junior test remained almost unchanged; in 7/30 patients, this score improved. The CBCL did not show significant changes in emotional or behavioral problems. Conclusions: Adjunctive treatment with PER did not negatively affect executive functions that could also be improved. No emotional/behavioral negative effects have been reported, and this suggests a good tolerability in the middle/long term.

KW - Adverse effects

KW - Behavior

KW - Children

KW - Executive functions

KW - Perampanel

UR - http://www.scopus.com/inward/record.url?scp=85077689517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077689517&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2019.106879

DO - 10.1016/j.yebeh.2019.106879

M3 - Article

AN - SCOPUS:85077689517

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

M1 - 106879

ER -